Coherus Management to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Coherus BioSciences, Nasdaq: CHRS, has announced that its senior management will present at the 23rd Annual H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Coherus BioSciences, Nasdaq: CHRS, has announced that its senior management will present at the 23rd Annual H.C. Wainwright Global Investment Conference on September 14, 2021, at 7 a.m. ET. The presentation will be accessible via the investors’ page on Coherus’ website. The company focuses on providing cost-effective medicines and aims to enhance its immuno-oncology franchise, leveraging revenue from its commercial biosimilars. For more details, visit www.coherus.com.
Details
News Market Reaction – CHRS
The recorded move for CHRS in the trading session of this news was -2.41%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
REDWOOD CITY, Calif., Sept. 10, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management will present at the 23rd Annual H.C. Wainwright Global Investment Conference. The presentation will be made available at 7 a.m. ET on Tuesday, September 14, 2021, during the virtual conference.
The audio portion of the presentation will be available on the investors’ page of the Coherus Biosciences website at http://investors.coherus.com.
About Coherus BioSciences
Coherus is a commercial stage biopharmaceutical company with the mission to increase access to cost-effective medicines that can have a major impact on patients’ lives and to deliver significant savings to the health care system. Coherus’ strategy is to build a leading immuno-oncology franchise funded with cash generated by its commercial biosimilar business. For additional information, please visit www.coherus.com.
Coherus Contact Information:
IR Contact:
McDavid Stilwell
Coherus BioSciences, Inc.
mstilwell@coherus.com
+1 (650) 395-0152
Media Contact:
Sheryl Seapy
Real Chemistry
sseapy@realchemistry.com
+1 (949) 903-4750
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.